Alendronate sodium is the world's most widely used anti-osteoporosis drugs, listed in the United States in 1993. It can significantly increase bone mineral density, reduce fracture risk, and it is the first-line treatment of osteoporosis drugs. Alendronate sodium is a resorption inhibitor of aminodiphosphonate bone, and has a strong affinity with bone hydroxyapatite. It can enter the bone matrix hydroxyapatite crystals. When the osteoclast dissolved crystals, the drug was released, causing the inhibition of osteoclast activity, and playing anti-bone resorption activity indirectly through the inhibition of bone resorption of osteoblasts.

It possesses the characteristics of the activity of anti-bone resorption and with no bone mineralization. Clinically used for the treatment of postmenopausal women with osteoporosis, to prevent hip and spine fractures. It is important to note that calcium and vitamin D supplements should be administered to all patients with osteoporosis, if they are unable to ingest enough calcium and vitamin D from their diet.

Osteoporosis is a disease that leads to an increased risk of fracture. It is characterized by a reduction in bone mineral density, a deterioration of bone microstructure, and changes in the amount and type of proteins within the bones. The main risk of osteoporosis is caused by increased risk of fracture in patients which is rarely happened in healthy human beings. This fracture is also known as fragile fractures. The common parts includes the spine, ribs, buttocks, wrist, etc., It is the main reason to the disability or death of the people with osteoporosis. Statistics show that the incidence of osteoporosis in the world is on the rise. The osteoporosis patients in the world have more than 200 million and the osteoporosis patients in China have about 70 million. Osteoporosis has become a key disease leading to a serious health hazard to human health, especially in middle-aged and elderly women.

Bisphosphonates are a generic class of prescription drugs for the treatment of osteoporosis, including etidronate, Alendronate sodium, risedronate, zoledronic acid, etc. Their chemical share similar structure and pharmacological effects.

Alendronate sodium, trade name Fosamax, is the world's most widely used anti-osteoporosis drugs. The product is the third generation of amino diphosphonate bone resorption inhibitors, and has a strong affinity with bone hydroxyapatite, playing anti-bone resorption role by inhibiting osteoclast activity. Its anti-bone resorption is 1000 times stronger than that of etidronate, and there is no bone mineralization inhibition. Mainly used for postmenopausal women with osteoporosis, it can increase the bone mass of the spine, vertebral body distortion, height reduction, fracture incidence (including the hip, spine, carpal) and so on.